Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials
Eric Plennevaux, Annick Moureau, José L Arredondo-García, Luis Villar, Punnee Pitisuttithum, Ngoc H Tran, Matthew Bonaparte, Danaya Chansinghakul, Diana L Coronel, Maïna L'Azou, R Leon Ochiai, Myew-Ling Toh, Fernando Noriega, Alain Bouckenooghe, Eric Plennevaux, Annick Moureau, José L Arredondo-García, Luis Villar, Punnee Pitisuttithum, Ngoc H Tran, Matthew Bonaparte, Danaya Chansinghakul, Diana L Coronel, Maïna L'Azou, R Leon Ochiai, Myew-Ling Toh, Fernando Noriega, Alain Bouckenooghe
Abstract
Background: We previously reported that vaccination with the tetravalent dengue vaccine (CYD-TDV; Dengvaxia) may bias the diagnosis of dengue based on immunoglobulin M (IgM) and immunoglobulin G (IgG) assessments.
Methods: We undertook a post hoc pooled analysis of febrile episodes that occurred during the active surveillance phase (the 25 months after the first study injection) of 2 pivotal phase III, placebo-controlled CYD-TDV efficacy studies that involved ≥31000 children aged 2-16 years across 10 countries in Asia and Latin America. Virologically confirmed dengue (VCD) episode was defined with a positive test for dengue nonstructural protein 1 antigen or dengue polymerase chain reaction. Probable dengue episode was serologically defined as (1) IgM-positive acute- or convalescent-phase sample, or (2) IgG-positive acute-phase sample and ≥4-fold IgG increase between acute- and convalescent-phase samples.
Results: There were 1284 VCD episodes (575 and 709 in the CYD-TDV and placebo groups, respectively) and 17673 other febrile episodes (11668 and 6005, respectively). Compared with VCD, the sensitivity and specificity of probable dengue definition were 93.1% and 77.2%, respectively. Overall positive and negative predictive values were 22.9% and 99.5%, respectively, reflecting the much lower probability of correctly confirming probable dengue in a population including a vaccinated cohort. Vaccination-induced bias toward false-positive diagnosis was more pronounced among individuals seronegative at baseline.
Conclusions: Caution will be required when interpreting IgM and IgG data obtained during routine surveillance in those vaccinated with CYD-TDV. There is an urgent need for new practical, dengue-specific diagnostic algorithms now that CYD-TDV is approved in a number of dengue-endemic countries.
Clinical trials registration: NCT01373281 and NCT01374516.
Figures
References
- World Health Organization. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated) Available at: . Accessed 9 December 2016.
- Plennevaux E, Sabchareon A, Limkittikul K et al. . Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: utility for efficacy evaluation and impact of future vaccine introduction. Vaccine 2016; 34:2707–12.
- Sabchareon A, Wallace D, Sirivichayakul C et al. . Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559–67.
- L’Azou M, Moureau A, Sarti E et al. ; CYD15 Primary Study Group Symptomatic dengue in children in 10 Asian and Latin American countries. N Engl J Med 2016; 374:1155–66.
- Capeding MR, Tran NH, Hadinegoro SR et al. ; CYD14 Study Group Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358–65.
- Villar L, Dayan GH, Arredondo-García JL et al. ; CYD15 Study Group Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113–23.
- Boaz M, Janosczyk H, Garg S et al. . Virological confirmation of suspected dengue in a phase 2 Latin American vaccine trial: implications for vaccine efficacy evaluation. Trials Vaccinol 2014; 3: 127–33.
- World Health Organization. Guidelines for the clinical evaluation of dengue vaccines in endemic areas 2008. Available at: . Accessed 22 March 2017.
- World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control 2009. Available at: . Accessed 22 March 2017.
- Shu PY, Chen LK, Chang SF et al. . Comparison of capture immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent assay (ELISA) and nonstructural protein NS1 serotype-specific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin Diagn Lab Immunol 2003; 10:622–30.
- Cucunawangsih , Lugito NP, Kurniawan A. Immunoglobulin G (IgG) to IgM ratio in secondary adult dengue infection using samples from early days of symptoms onset. BMC Infect Dis 2015; 15: 276.
- Prince HE, Yeh C, Lapé-Nixon M. Utility of IgM/IgG ratio and IgG avidity for distinguishing primary and secondary dengue virus infections using sera collected more than 30 days after disease onset. Clin Vaccine Immunol 2011; 18:1951–6.
- Innis BL, Nisalak A, Nimmannitya S et al. . An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 1989; 40:418–27.
- Karyana IPG, Santoso H, Arhana BNP. The value of IgG to IgM ratio in predicting secondary dengue infection. Paediatrica Indonesiana 2006; 46:113–7.
- Peeling RW, Artsob H, Pelegrino JL et al. . Evaluation of diagnostic tests: dengue. Nat Rev Microbiol 2010; 8:S30–8.
- Olivera-Botello G, Coudeville L, Fanouillere K et al. ; CYD-TDV Vaccine Trial Group Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2-16 years in Asia and Latin America. J Infect Dis 2016; 214:994–1000.
Source: PubMed